GWPH GW Pharmaceuticals Plc

86.58
+4.78  (+6%)
Previous Close 81.8
Open 85
Price To Book 3.69
Market Cap 2,682,043,465
Shares 30,977,633
Volume 714,836
Short Ratio
Av. Daily Volume 593,101
Stock charts supplied by TradingView

NewsSee all news

  1. GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That EPIDIOLEX® (cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance

    - Descheduling will enable prescribing free of the previous Schedule V requirements - CARLSBAD, Calif., April 06, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH, "GW, " "the Company" or "the Group")),

  2. GW Pharmaceuticals and Greenwich Biosciences Announce FDA Acceptance of sNDA Filing with Priority Review for EPIDIOLEX® (cannabidiol) in the Treatment of Seizures Associated with Tuberous Sclerosis Complex

    CARLSBAD, Calif., March 31, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S.

  3. GW Pharmaceuticals submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of EPIDYOLEX®, (cannabidiol) oral solution, for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC)

    LONDON, March 13, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW", "the Company" or "the Group"), a world leader in discovering, developing and commercialising cannabinoid prescription medicines,

  4. JAMA Neurology Publishes Results from Positive Phase 3 Trial of EPIDIOLEX® (cannabidiol) oral solution in Children with Seizures Associated with Dravet Syndrome

    CARLSBAD, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH, GW, the Company or the Group)), the world leader in the science, development, and commercialization of cannabinoid prescription

  5. GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress

    - Total revenue of $109.1 million for the fourth quarter and $311.3 million for the full year - - Total Epidiolex® net product sales of $104.5 million for the fourth quarter and $296.4 million for the first full year of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data released February 7, 2017.
Tetrahydrocannabinol (THC) and cannabidiol (CBD)
Glioblastoma Multiform- cancer
Phase 2 open-label trial underway - noted February 25, 2020.
GWP42006 (CBDV)
Rett syndrome
Phase 3 initiated December 2016. Part A nearing completion, unlikely to continue through to Part B.
Epidiolex
Infantile spasms (IS)
Phase 2 trial did not meet endpoint
GWP42004
Type 2 diabetes
Phase 3 trials failed. Evaluating whether there are any next steps
Sativex
Cancer pain
Phase 2 data released February 21, 2018 - primary endpoint not met.
GWP42006 (CBDV)
Epilepsy
Phase 2b trial to commence 1H 2020.
GWP42003
Schizophrenia
Approval announced June 25, 2018.
Epidiolex
Dravet Syndrome and Lennox-Gastaut syndrome
PDUFA date under priority review July 31, 2020.
Epidiolex
Tuberous Sclerosis Complex
Phase 3 trial planned for 2Q 2020.
Sativex
Spasticity due multiple sclerosis
Phase 2 data due 2020.
GWP42006 (CBDV)
Autism
Phase 3 trial has commenced - May 6, 2019.
Epidiolex
Rett syndrome
Phase 3 data to be presented at AAN May 7, 2019.
Epidiolex GWPCARE2
Dravet Syndrome

Latest News

  1. GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That EPIDIOLEX® (cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance

    - Descheduling will enable prescribing free of the previous Schedule V requirements - CARLSBAD, Calif., April 06, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH, "GW, " "the Company" or "the Group")),

  2. GW Pharmaceuticals and Greenwich Biosciences Announce FDA Acceptance of sNDA Filing with Priority Review for EPIDIOLEX® (cannabidiol) in the Treatment of Seizures Associated with Tuberous Sclerosis Complex

    CARLSBAD, Calif., March 31, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S.

  3. GW Pharmaceuticals submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of EPIDYOLEX®, (cannabidiol) oral solution, for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC)

    LONDON, March 13, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW", "the Company" or "the Group"), a world leader in discovering, developing and commercialising cannabinoid prescription medicines,

  4. JAMA Neurology Publishes Results from Positive Phase 3 Trial of EPIDIOLEX® (cannabidiol) oral solution in Children with Seizures Associated with Dravet Syndrome

    CARLSBAD, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH, GW, the Company or the Group)), the world leader in the science, development, and commercialization of cannabinoid prescription

  5. GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress

    - Total revenue of $109.1 million for the fourth quarter and $311.3 million for the full year - - Total Epidiolex® net product sales of $104.5 million for the fourth quarter and $296.4 million for the first full year of

  6. GW Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference

    LONDON and CARLSBAD, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH, GW, the Company or the Group)), a world leader in the science, development, and commercialization of cannabinoid

  7. GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Fourth Quarter and Year Ending December 31, 2019 and Host Conference Call on February 25th, 2020

    LONDON and CARLSBAD, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH, "GW" or "the Company")), a biopharmaceutical company focused on discovering, developing and commercializing novel

  8. GW Pharmaceuticals and Greenwich Biosciences Submit Supplemental New Drug Application to U.S. FDA for Epidiolex® (cannabidiol) for the Treatment of Tuberous Sclerosis Complex

    LONDON and CARLSBAD, Calif., Feb. 03, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH, GW, the Company or the Group)), the world leader in the science, development, and commercialization of cannabinoid

  9. GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

    - Total preliminary net product sales of approximately $108 million for the fourth quarter and approximately $309 million for the full year - - Total Epidiolex® preliminary net product sales of approximately $104 million

  10. GW Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

    LONDON and CARLSBAD, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH, GW, the Company or the Group)), the world leader in the science, development, and commercialization of cannabinoid

  11. Greenwich Biosciences, a GW Pharmaceuticals Company, Presents New Data for EPIDIOLEX® (cannabidiol) in Patients with Tuberous Sclerosis Complex (TSC) at the American Epilepsy Society Annual Meeting

    CARLSBAD, Calif., Dec. 07, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S.

  12. GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

    LONDON and CARLSBAD, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with

  13. GW Pharmaceuticals to Present at Upcoming Investor Conferences

    CARLSBAD, Calif., Nov. 22, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ:GWPH, GW, the Company or the Group)), the world leader in the science, development,

  14. GW Pharmaceuticals receives positive NICE recommendation for EPIDYOLEX® (cannabidiol) oral solution for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

    GW also welcomes the positive guideline recommendation for Sativex® (nabiximols) for the treatment of spasticity due to multiple sclerosis as part of NICE's evaluation of cannabis-based medicinal products (CBMPs)

  15. GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019

    - Epidiolex U.S. year to date net sales of $188.0 million, including Q3 net sales of $86.1 million - - Conference call today at 4:30 p.m. ET - CARLSBAD, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc

  16. GW Pharmaceuticals to Present at Upcoming Investor Conferences

    CARLSBAD, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ:GWPH, GW, the Company or the Group)), the world leader in the science, development,

  17. GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30, 2019 and Host Conference Call on November 5, 2019

    CARLSBAD, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH, "GW" or "the Company")), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics

  18. Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman

    Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces the appointment of Thomas Lynch as the new non-Executive Chairman of its Board, from 1 September 2019.

  19. GW Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2nd, 2019

    CARLSBAD, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ:GWPH, GW, the Company or the Group)), the world leader in the development and

  20. Why the Magic Mushroom Story Could be as Big as the Cannabis Boom

    PALM BEACH, Florida, Sept. 24, 2019 /PRNewswire/ -- As cannabis legalization spreads, another drug may soon follow in its footsteps -- psilocybin mushrooms.  In fact, analysts argue mushrooms may hold untapped medical

  21. GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

    Cannabidiol oral solution is the first plant-derived cannabis-based medicine to be approved by the European Medicines Agency (EMA) Cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a

  22. The Most Impressive Cannabis Statistics That Should not be Overlooked

    PALM BEACH, Florida, Sept. 5, 2019 /PRNewswire/ -- Cannabis has become the biggest story of the decade. Not only did Canada approve its use in 2018, the U.S. government has become aggressive in its attempt to legalize

  23. GW Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11th, 2019

    CARLSBAD, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ:GWPH, GW, the Company or the Group)), the world leader in the science, development,